A pharmaceutical composition for therapeutically treating...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/40 (2006.01) A61K 31/4015 (2006.01) C07D 207/26 (2006.01)

Patent

CA 2187086

A pharmaceutical composition for therapeutically treating tardive dyskinesia, which comprises a compound having an enzyme-inhibitory activity against a phospho- diesterase as the active ingredient, is now provided. Rolipram is preferred as the active ingredient. When rolipram is administered to such rats as experimental model, which have tardive dyskinesia induced by consecu- tive administrations of haloperidol, there can be obtained such curative effect that the symptoms of tardive dyskinesia are suppressed dose-dependently.

Composition médicinale destinée à traiter la dyskinésie tardive, contenant un composé ayant une activité inhibitrice de la phosphodiestérase en tant qu'ingrédient actif et dont un exemple préféré est le rolipram. Lorsque ledit composé est administré à des rats d'expérimentation atteints de dyskinésie tardive induite par l'administration chronique d'halopéridol, il présente un effet thérapeutique de suppression du symptôme de dyskinésie tardive selon la dose.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

A pharmaceutical composition for therapeutically treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with A pharmaceutical composition for therapeutically treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and A pharmaceutical composition for therapeutically treating... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1500046

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.